Breaking News, Financial News

Financial Report: Amgen 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 1Q Revenues: $3.6 billion (-2%) 1Q Earnings: $1.1 billion (+2%) Comments: Worldwide sales of Aranesp decreased 25% to $761 million, with U.S. sales down 38% to $405 million due to prescribing restrictions as a result of adverse cardiovascular events. Epogen sales were $554 million (-11%) due to a reduction in dose/utilization due to ESA label changes and implementation of the Erythropoietin Monitoring Policy (EMP). Combined sales of Neulasta and Neupogen were $1.1 billion (+7%). S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters